Latest news
25 items- SECCryoLife Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - ARTIVION, INC. (0000784199) (Filer)
- NEWSCryoLife Announces Corporate Rebranding And Changes Name To Artivion; Will Change Ticker To 'AORT' Effective Jan. 24CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY." "Through a combination of legacy products and strategic acquisitions and divestitures over the last five years, we have
- PRCryoLife Announces Corporate Rebranding and Changes Name to ArtivionATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."
- NEWSMorgan Stanley Maintains Equal-Weight on Cryolife, Lowers Price Target to $25Morgan Stanley maintains Cryolife (NYSE:CRY) with a Equal-Weight and lowers the price target from $29 to $25.
- ANALYSTMorgan Stanley reiterated coverage on Cryolife with a new price targetMorgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $25.00 from $29.00 previously
- SECSEC Form 8-A12B/A filed by CryoLife, Inc. (Amendment)8-A12B/A - CRYOLIFE INC (0000784199) (Filer)
- SECCryoLife, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - CRYOLIFE INC (0000784199) (Filer)
- INSIDERSEC Form 4: Horton Amy sold $46,422 worth of shares (2,500 units at $18.57) and gifted 1,500 shares, decreasing direct ownership by 4% to 85,282 units4 - CRYOLIFE INC (0000784199) (Issuer)
- INSIDERSEC Form 4: Davis John E bought $10,398 worth of shares (600 units at $17.33), increasing direct ownership by 0.83% to 72,499 units4 - CRYOLIFE INC (0000784199) (Issuer)
- NEWS3 Stocks Insiders Are BuyingWhen insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Six Flags Entertainment The Trade: Six Flags Entertainment Corporation (NYSE:SIX) Director Arik W Ruchim acquired a total of 250000 shares at an average price of $37.24. To acquire these shares, it cost $9,310,29
- INSIDERSEC Form 4: Semedo Anthony B. was granted 4,992 shares and bought $260,400 worth of shares (15,000 units at $17.36)4 - CRYOLIFE INC (0000784199) (Issuer)
- SECCryoLife, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - CRYOLIFE INC (0000784199) (Filer)
- PRCryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services ForumATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available. For more information on the company, please visit CryoLife's website, www.cryolife.com, on the Investor Relations page. About CryoLife, Inc.Headquartered in suburban Atlanta, Georgia,
- INSIDERSEC Form 4: Maney Rochelle L. returned $4,539 worth of shares to the company (214 units at $21.21), decreasing direct ownership by 1% to 14,108 units4 - CRYOLIFE INC (0000784199) (Issuer)
- SECSEC Form 10-Q filed by CryoLife, Inc.10-Q - CRYOLIFE INC (0000784199) (Filer)
- SECCryoLife, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CRYOLIFE INC (0000784199) (Filer)
- PRCryoLife Reports Third Quarter 2021 Financial ResultsATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina
- PRCryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial ResultsATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc. To participate in the conference call dial 862-298-0702 a few minutes
- INSIDERSEC Form 3: New insider Semedo Anthony B. claimed no ownership of stock in the company3 - CRYOLIFE INC (0000784199) (Issuer)
- SECSEC Form DEFA14A filed by CryoLife, Inc.DEFA14A - CRYOLIFE INC (0000784199) (Filer)
- SECSEC Form DEF 14A filed by CryoLife, Inc.DEF 14A - CRYOLIFE INC (0000784199) (Filer)
- SECSEC Form PRE 14A filed by CryoLife, Inc.PRE 14A - CRYOLIFE INC (0000784199) (Filer)
- SECCryoLife, Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CRYOLIFE INC (0000784199) (Filer)
- PRAnthony Semedo Joins CryoLife Board of DirectorsATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021. "We are thrilled to welcome Tony, a leader in the aortic space, to our board of directors," commented Pat Mackin, Chairman, President, and Chief Executive Officer. "Tony's demonstrated ability to lead, grow, and integrate diversified global divisions in the medical device space as well as his experience managing robust R&D, quali
- INSIDERSEC Form 4: Holloway Jean F sold $17,566 worth of Common Stock (663 units at $26.49), decreasing direct ownership by 0.76% to 86,567 units4 - CRYOLIFE INC (0000784199) (Issuer)